Exhibit 99.1

                                  NEWS RELEASE


CONTACT:  Gary S. Maier
          Maier & Company, Inc.
          (310) 442-9852


                      CYTOMEDIX NAMES CORPORATE CONTROLLER


         ROCKVILLE, Maryland - June 16, 2005 - Cytomedix (AMEX: GTF) today
announced the appointment of Andrew Maslan to the new position of corporate
controller, effective, July 1, 2005.

         Maslan, 35, most recently served as controller for BioReliance
Corporation, based in Rockville, Maryland, which was acquired by Invitrogen
(Nasdaq: IVGN) in February 2004. Earlier, he held positions with two other
Rockville, Maryland-based companies, serving as a principal with GlobeTraders,
Inc., and senior accountant for Providence Laboratory Associates. He began his
professional career serving as an auditor for KPMG Peat Marwick.

         "The establishment of a dedicated corporate controller position
reflects the importance we place on maintaining proper systems and procedures.
Andrew's broad range of finance and leadership experience and his
entrepreneurial, results-oriented approach to his work are important qualities
and we look forward to his contributions on our team," said Dr. Kshitij Mohan,
chief executive officer of Cytomedix.

         Maslan earned a Bachelor of Science degree in accountancy from Miami
University in Oxford, Ohio.

ABOUT THE COMPANY

         Cytomedix, Inc. is a biotechnology company specializing in processes
and products derived from autologous platelet releasates for uses in the
treatment of wounds and other applications. The current offering is the
AutoloGel(tm) system, a technology that utilizes an autologous platelet gel
composed of multiple growth factors and fibrin matrix. The company is conducting
a well- controlled, blinded, prospective, multi-center clinical trial on the use
of its technology in healing diabetic foot ulcers. Cytomedix is working with
healthcare providers to offer an advanced therapy at the point-of-care in
multiple settings. Additional information is available at: www.cytomedix.com.

         Statements contained in this press release not relating to historical
facts are forward-looking statements that are intended to fall within the safe
harbor rule for such statements under the Private Securities Litigation Reform
Act of 1995. The information contained in the forward-looking statements is
inherently uncertain, and Cytomedix's actual results may differ materially due
to a number of factors, many of which are beyond Cytomedix's ability to predict


or control, including among others, the success of new sales initiatives,
governmental regulation, acceptance by the medical community and competition.
These forward-looking statements are subject to known and unknown risks and
uncertainties that could cause actual events to differ from the forward-looking
statements. More information about some of these risks and uncertainties may be
found in the reports filed with the Securities and Exchange Commission by
Cytomedix, Inc.

                             #      #      #